Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I M Robbins

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Chest|November 20, 2001
Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertensionI M Robbins, R J Barst, L J Rubin, et al.
The European Respiratory Journal|April 16, 2004
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertensionP Bresser, P F Fedullo, W R Auger, et al.
The European Respiratory Journal|September 11, 2004
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2M Humbert, R J Barst, I M Robbins, et al.
Respiratory Medicine|November 3, 2009
T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertensionE D Austin, M T Rock, C A Mosse, et al.
The European Respiratory Journal|March 2, 2006
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertensionI M Robbins, S M Kawut, D Yung, et al.
Lancet (London, England)|October 13, 2001
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyR N Channick, G Simonneau, O Sitbon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 8, 2014
Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurementC M Shaver, J L Castilho, D N Cohen, et al.
Vascular Pharmacology|May 14, 2005
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectAdaani E Frost, D Langleben, R Oudiz, et al.
Journal of Medical Genetics|December 20, 2003
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasiaR E Harrison, J A Flanagan, M Sankelo, et al.
Annals of Internal Medicine|March 25, 2000
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialD B Badesch, V F Tapson, M D McGoon, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Chest|November 20, 2001
Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertensionI M Robbins, R J Barst, L J Rubin, et al.
The European Respiratory Journal|April 16, 2004
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertensionP Bresser, P F Fedullo, W R Auger, et al.
The European Respiratory Journal|September 11, 2004
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2M Humbert, R J Barst, I M Robbins, et al.
Respiratory Medicine|November 3, 2009
T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertensionE D Austin, M T Rock, C A Mosse, et al.
The European Respiratory Journal|March 2, 2006
A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertensionI M Robbins, S M Kawut, D Yung, et al.
Lancet (London, England)|October 13, 2001
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyR N Channick, G Simonneau, O Sitbon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 8, 2014
Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurementC M Shaver, J L Castilho, D N Cohen, et al.
Vascular Pharmacology|May 14, 2005
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectAdaani E Frost, D Langleben, R Oudiz, et al.
Journal of Medical Genetics|December 20, 2003
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasiaR E Harrison, J A Flanagan, M Sankelo, et al.
Annals of Internal Medicine|March 25, 2000
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialD B Badesch, V F Tapson, M D McGoon, et al.
Pageof 2